ADMA
ADMA Biologics, Inc.19.17
-0.56-2.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.57BP/E (TTM)
22.29Basic EPS (TTM)
0.86Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
ADMA refinances with $300M facility
ADMA Biologics secured a $300 million senior secured credit facility on August 5, 2025, comprising a $75 million term loan and $225 million revolving line, maturing August 5, 2028, to refinance its prior Ares facility and support working capital, share repurchases, and general purposes. Interest accrues at ABR plus 1.50%-2.00% or Term SOFR plus 2.50%-3.00%, based on leverage, with a 0.30%-0.35% commitment fee on undrawn revolver amounts. The deal imposes a 2.50:1.00 maximum leverage ratio and 1.20:1.00 minimum fixed charge coverage, secured by all assets; yet, it lowers costs while enhancing liquidity. Strong covenants bind operations.
10-Q
Q2 FY2025 results
ADMA Biologics posted solid Q2 FY2025 results, with revenues climbing 14% year-over-year to $122.0M, fueled by ASCENIV's growing acceptance among physicians and payers, while BIVIGAM faced a minor hit from a voluntary lot withdrawal. Gross margins edged up to 55.1% from 53.6%, thanks to a richer mix of high-margin IG sales, and operating income rose 9% to $42.8M, though SG&A swelled 34% on staffing for expansion. Diluted EPS held steady at $0.14, aligning with 248.6M shares, while free cash flow turned negative at -$5.8M (derived) amid inventory builds and $7.1M capex. Cash sat at $90.3M with $75.0M debt at ~8-11% rates, bolstered by a $300M JPM facility in August for refinancing and buybacks—$15.1M repurchased already. Yet regulatory scrutiny on plasma supply chains lingers as a key risk.
8-K
Annual meeting results approved
ADMA Biologics held its 2025 Annual Meeting on June 4, electing Jerrold B. Grossman and Lawrence P. Guiheen as Class III directors despite some withheld votes. Stockholders ratified KPMG LLP as auditors for the year ending December 31, 2025, approved executive pay on an advisory basis, and favored annual say-on-pay votes. With 86% turnout, the results signal strong governance alignment. No surprises here.
IPO
Employees
Sector
Industry
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
ARTV
Artiva Biotherapeutics, Inc.
4.55-1.75
BIVI
BioVie Inc.
1.43+0.00
HCWB
HCW Biologics Inc.
1.78-0.09
IMTX
Immatics N.V.
10.09+0.11
IVBXF
Innovent Biologics Inc.
10.55+0.00
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SMMT
Summit Therapeutics Inc.
17.23-0.15
XBIT
XBiotech Inc.
2.45-0.08
ZIVO
Zivo Bioscience, Inc.
9.00+0.00